IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?

Bone Marrow Transplant. 1991:7 Suppl 2:145.

Authors

P Tiberghien¹, E Racadot, T Fest, B Lioure, J Pariset, M Delain, L Voillat, M Flesch, D Amsallem, E Plouvier, et al.

Affiliation

¹ Bone Marrow Transplantation Unit, C.H.U.J. Minjoz, Besancon, France.

PMID: 1878686

No abstract available

Publication types

Clinical Trial

MeSH terms

Adolescent
Adult
Bone Marrow Transplantation*
Child
Combined Modality Therapy
Drug Evaluation
Hodgkin Disease / immunology
Hodgkin Disease / pathology
Hodgkin Disease / surgery
Hodgkin Disease / therapy*
Humans
Immunologic Factors / pharmacology
Immunologic Factors / therapeutic use*
Interleukin-2 / pharmacology
Interleukin-2 / therapeutic use*
Killer Cells, Lymphokine-Activated / drug effects
Killer Cells, Lymphokine-Activated / immunology
Killer Cells, Lymphokine-Activated / pathology*
Killer Cells, Natural / drug effects
Killer Cells, Natural / immunology
Transplantation, Autologous

Substances

Immunologic Factors
Interleukin-2